Skip to main content
Log in

Ocular Availability of Gentamicin in Small Animals After Topical Administration of a Conventional Eye Drop Solution and a Novel Long Acting Bioadhesive Ophthalmic Drug Insert

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose. Gentamicin eye drop solutions have a short precorneal residence time. The present study investigates the effect of gentamicin using a new long acting delivery Bioadhesive Ophthalmic Insert (BODI) in healthy dogs and rabbits and compares the results with a conventional regimen using an eye drop solution.

Methods. In vivo assays were performed on animals after deposition of one BODI and instillations of an eye drop solution. Tear samples were collected over 72 hours and 60 minutes, in the case of inserts and eye drop solution respectively. The gentamicin concentration profiles in tear fluid (determined by a fluorescent polarization immunoassay technique) was individually analyzed, in each animal, in relation with the minimum inhibitory concentration observed in vitro against some bacteria. A non classical pharmacokinetic approach was used for the analysis of the topically applied drug substance, involving two parameters: the efficacy area under the curve (AUCeff) and the efficacy time (teff).

Results. In the case of the eye drop solution, the AUCeff were higher in dogs (2.80 103 − 3.64 103 [µg ml−1 h]) than in rabbits (0.64 · 103 − 0.95 · 103 [µg ml−1h]); the teff had a similar behavior: 6-15 [h] in dogs and 2-6 [h] in rabbits. In the case of BODIs, the AUCeff and the teff were quite similar between dogs and rabbits: 190 103 − 205 103 [µg ml−1 h] and 70-76 [h], respectively. The AUCeff and the teffwere always much higher in the case of BODIs than for the eye drop solution both in dogs and rabbits.

Conclusions. This study shows that topical administration of gentamicin using BODIs can improve treatment due to the decreasing number of applications while ensuring an effective level of antibiotic in tears controlled by the device.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

REFERENCES

  1. F. Q. Liang, R. S. Viola, M. del Cerrro, and V. Aquavella. Noncross-linked collagen discs and cross-linked collagen shields in the delivery of gentamicin to rabbits eyes. Invest. Ophthalmol. Vis. Sci. 33:2194–2198 (1992).

    Google Scholar 

  2. H. Ozawa, S. Hosaka, T. Kunitomo, and H. Tanzawa. Ocular inserts for controlled release of antibiotics. Biomaterials 4:170–174 (1983).

    Google Scholar 

  3. M. F. Saettone, B. Giannaccini, G. Marchesini, G. Galli, and E. Chiellini. Polymeric inserts for sustained ocular delivery of pilocarpine. Pol. Sci. Technol. 34:409–420 (1986).

    Google Scholar 

  4. J. L. Baum, M. Barza, D. Sushan, and L. Weinstein. Concentration of gentamicin in experimental corneal ulcers: topical vs subconjunctival therapy. Arch. Ophthalmol. 92:315–317 (1974).

    Google Scholar 

  5. J. R. Yuen, and G. S. Jaresko. Pharmacokinetics of ocular infections. J. Pharm. Prac. 9:247–268 (1991).

    Google Scholar 

  6. S. S. Chrai, M. C. Makoid, S. T. Eriksen, and J. R. Robinson. Lacrimal and instilled fluid dynamics in rabbit eyes. J. Pharm. Sci. 62:1112–1120 (1973).

    Google Scholar 

  7. S. S. Chrai, M. C. Makoid, S. P. Eriksen, and J. R. Robinson. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J. Pharm. Sci. 63:333–338 (1974).

    Google Scholar 

  8. S. El-Shanaway. Ocular delivery of pilocarpine from ocular inserts. STP Pharm. Sci. 2:337–341 (1992).

    Google Scholar 

  9. F. Gurtler, and R. Gurny. Patent literature review of ophthalmic inserts. Drug Dev. Ind. Pharm. 21:1–18 (1995).

    Google Scholar 

  10. F. Gurtler, V. Kaltsatos, B. Boisramé, and R. Gurny. Long-acting ocular inserts for treatment of external infections in animals: clinical investigations. Conf. Proceed. International Symposium Controlled Release of Biactive Materials. Nice (France) 1994.

  11. F. Gurtler, V. Kaltsatos, B. Boisramé, and R. Gurny. Long-acting ocular inserts for treatment of external infections in animals: clinical investigations. J. Contr. Rel. 33:231–236 (1995).

    Google Scholar 

  12. S. R. Popelka, D. M. Miller, J. T. Holen, and D. M. Kelso. Fluorescence polarization immunoassay II. Analyzer for rapid, precise measurement of fluorescence polarization with use of disposable cuvettes. Clin. Chem. 27:1198–1201 (1981).

    Google Scholar 

  13. M. E. Jolley, S. D. Stroupe, K. S. Schwenzer, C. J. Wang, M. Lu-Steffes, H. D. Hill, S. R. Popelka, J. T. Holen, and D. M. Kelso. Fluorescence polarization immunoassay III. An automated system for therapeutic drug determination. Clin. Chem. 27:1575–1579 (1981).

    Google Scholar 

  14. M. E. Jolley, S. D. Stroupe, C. H. J. Wang, H. N. Panas, C. L. Keegan, R. L. Schmidt, and K. S. Schwenzer. Fluorescence polarization immunoassay I. Monitoring aminoglycoside antibiotics in serum and plasma. Clin. Chem. 27:1190–1197 (1981).

    Google Scholar 

  15. Garamycin®, in: J. Morant and H. Ruppaner (eds.), Compendium Suisse des médicaments, Bâle: Documed; 1995: 761.

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gurtler, F., Kaltsatos, V., Boisramé, B. et al. Ocular Availability of Gentamicin in Small Animals After Topical Administration of a Conventional Eye Drop Solution and a Novel Long Acting Bioadhesive Ophthalmic Drug Insert. Pharm Res 12, 1791–1795 (1995). https://doi.org/10.1023/A:1016242528222

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1016242528222

Navigation